What is SciSafe?
SciSafe operates as a critical node in the global pharmaceutical supply chain, providing cGMP-compliant biorepository services that span over 15 years of industry expertise. By offering precision cold chain logistics, clinical trial management, and secure storage for sensitive cell lines and biologics, the company serves as an essential partner for research institutions and pharmaceutical developers. Their infrastructure is designed to mitigate risk through real-time inventory visibility and stringent regulatory adherence, ensuring that the integrity of scientific assets remains uncompromised throughout the storage lifecycle. As a leader in biostorage technology, SciSafe bridges the gap between laboratory innovation and commercial distribution, maintaining the stability of critical materials that underpin modern medical breakthroughs.
How much funding has SciSafe raised?
SciSafe has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in SciSafe
PPP
Public-Private Partnership
What's next for SciSafe?
With the successful acquisition of $0, SciSafe is positioned to scale its global footprint and enhance its technological infrastructure. The company is expected to prioritize the expansion of its automated storage facilities and the integration of advanced monitoring systems to meet the evolving requirements of the life sciences sector. By leveraging this late-stage investment, SciSafe aims to solidify its competitive advantage in the cold chain market, potentially exploring strategic acquisitions or geographic diversification to better serve its international client base. The focus remains on maintaining operational excellence while scaling to meet the increasing volume of clinical trial samples and high-value biologics requiring specialized, compliant handling.
See full SciSafe company page
